Business Context and Reporting Period
This Form 8-K Current Report was filed by Alkermes Plc. on July 6, 2026. The filing addresses the termination of a material definitive agreement with Amneal Pharmaceuticals LLC regarding the distribution of an authorized generic version of VIVITROL.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The document focuses exclusively on the contractual termination event.
Material Changes
- Agreement Termination: On July 6, 2026, Alkermes and Amneal terminated the Authorized Generic Product Supply Agreement originally executed on September 9, 2025.
- Cause: The termination followed Alkermes notifying Amneal of unmet terms. Amneal subsequently elected not to order any batches under the agreement prior to the remedy period expiring.
- Financial Impact: Alkermes incurred no penalties. No further payments or obligations are owed by either party following the termination.
- Legal Resolution: Both parties agreed to release all claims against one another arising from the agreement.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of new risks beyond the resolution of the specific agreement dispute. The unusual item is the early termination of the supply agreement without financial penalty.
Investor Verification Checklist
- Confirm the status of VIVITROL sales and the impact of the terminated authorized generic arrangement on market share.
- Verify that no contingent liabilities or hidden costs remain from the terminated agreement.
- Review the original September 2025 agreement (Exhibit 10.1 to the Q3 2025 10-Q) to understand the specific terms Amneal failed to meet.
- Assess whether this termination signals broader challenges in Alkermes' commercial partnerships or supply chain strategy.